312: Medicare coverage for GLP-1 drugs, AI, and health care at the presidential debate
Jun 27, 2024
auto_awesome
Guests Brittany Trang and Rachel Cohrs Zhang discuss AI in drug development, Medicare coverage for GLP-1 drugs, H5N1 bird flu outbreak, and proposals for obesity drug coverage in Washington, with insights on the first presidential debate's healthcare topics.
Proposal for Medicare to cover weight loss drugs targets seniors with obesity, sparking debate on preventive treatment approach.
Biotech companies exploring AI for drug development and diversifying into new therapeutic areas for financial stability.
Deep dives
Legislation for Medicare Coverage of Weight Loss Drugs
Lawmakers are considering a proposal to allow Medicare to cover weight loss medications, aiming to prevent individuals from losing coverage when transitioning to Medicare. The revised bill targets seniors with obesity specifically, unlike the prior bill that had a larger patient population eligibility. The bill's focus on a narrower group also raises questions about the inclusion of behavioral intensive therapy, shifting the approach to preventive treatment.
AI-focused Drug Development and Enzyme Research in Biotech
In the biotech industry, there is a growing interest in AI for drug development, with companies like Flagship's Celerity utilizing unconventional computational and AI methods to target diseased cells and develop interventions. Basecamp's unique focus on enzymes from biodiverse samples aims to enhance protein-generating AI for varied applications like pharmaceuticals. The diversification from traditional protein research toward enzymes marks a significant shift with potential benefits.
Ongoing Debates and Developments in Biotech Companies
Recent developments in biotech companies, like Amelix's unexpected shift to invest in a GLP-1 drug post-ALS drug setback, indicate industry trends embracing new therapeutic areas for financial viability. In contrast, Grail's journey on the stock exchange post-FTC intervention reflects ongoing challenges in healthcare adoption for technologies like liquid biopsies. Sarepta's gene therapy approval underscores FDA flexibility debates around drug standards and patient benefits, raising pivotal questions for the biotech landscape.
STAT health tech reporter Brittany Trang guest co-hosts "The Readout LOUD" this week, where we discuss AI for drug development, the latest in the H5N1 bird flu outbreak, a surprise entrant to the GLP-1 field, and more news in the life sciences. And STAT chief Washington correspondent Rachel Cohrs Zhang joins the podcast to talk about a new proposal for obesity drug coverage in Washington and what to expect from the first presidential debate.
Get the Snipd podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered podcast player
Listen to all your favourite podcasts with AI-powered features
Discover highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share & Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered podcast player
Listen to all your favourite podcasts with AI-powered features
Discover highlights
Listen to the best highlights from the podcasts you love and dive into the full episode